Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scot C Remick

Showing results (31-40 of 93) with videos related to

Pageof 10
Sort By:
Clinical Cardiology|December 17, 2009
Myocardial stunning following combined modality combretastatin-based chemotherapy: two case reports and review of the literatureShyam Bhakta, Susan M Flick, Matthey M Cooney, et al.
Journal of Magnetic Resonance Imaging : JMRI|August 8, 2006
Model-free parameters from dynamic contrast-enhanced-MRI: sensitivity to EES volume fraction and bolus timingJohn A Jesberger, Niusha Rafie, Jeffrey L Duerk, et al.
Journal of the National Cancer Institute|September 12, 2014
Cancer treatment-related cardiotoxicity: current state of knowledge and future research prioritiesNonniekaye Shelburne, Bishow Adhikari, Joanna Brell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?Willem J van Heeckeren, Shyam Bhakta, Jose Ortiz, et al.
Thyroid : Official Journal of the American Thyroid Association|November 2, 2012
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroidPanayiotis Savvides, Govardhanan Nagaiah, Pierre Lavertu, et al.
Oncology Reports|January 12, 2023
Targeting the secreted RGDKGE collagen fragment reduces PD‑L1 by a proteasome‑dependent mechanism and inhibits tumor growthJennifer M Caron, Xianghua Han, Christine W Lary, et al.
Current Opinion in Hematology|October 16, 2007
Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosisWillem J van Heeckeren, Sharon L Sanborn, Ajita Narayan, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2009
A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairmentChristopher J Sweeney, Chris Takimoto, Leslie Wood, et al.
Neuroepidemiology|April 16, 2019
Disability-Adjusted Life-Years Due to Stroke in KenyaLydia Kaduka, Erastus Muniu, Jane Mbui, et al.
Frontiers in Oncology|July 8, 2014
Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyondAlexander Chi, Nam Phong Nguyen, James S Welsh, et al.
Pageof 10

Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
Clinical Cardiology|December 17, 2009
Myocardial stunning following combined modality combretastatin-based chemotherapy: two case reports and review of the literatureShyam Bhakta, Susan M Flick, Matthey M Cooney, et al.
Journal of Magnetic Resonance Imaging : JMRI|August 8, 2006
Model-free parameters from dynamic contrast-enhanced-MRI: sensitivity to EES volume fraction and bolus timingJohn A Jesberger, Niusha Rafie, Jeffrey L Duerk, et al.
Journal of the National Cancer Institute|September 12, 2014
Cancer treatment-related cardiotoxicity: current state of knowledge and future research prioritiesNonniekaye Shelburne, Bishow Adhikari, Joanna Brell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?Willem J van Heeckeren, Shyam Bhakta, Jose Ortiz, et al.
Thyroid : Official Journal of the American Thyroid Association|November 2, 2012
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroidPanayiotis Savvides, Govardhanan Nagaiah, Pierre Lavertu, et al.
Oncology Reports|January 12, 2023
Targeting the secreted RGDKGE collagen fragment reduces PD‑L1 by a proteasome‑dependent mechanism and inhibits tumor growthJennifer M Caron, Xianghua Han, Christine W Lary, et al.
Current Opinion in Hematology|October 16, 2007
Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosisWillem J van Heeckeren, Sharon L Sanborn, Ajita Narayan, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2009
A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairmentChristopher J Sweeney, Chris Takimoto, Leslie Wood, et al.
Neuroepidemiology|April 16, 2019
Disability-Adjusted Life-Years Due to Stroke in KenyaLydia Kaduka, Erastus Muniu, Jane Mbui, et al.
Frontiers in Oncology|July 8, 2014
Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyondAlexander Chi, Nam Phong Nguyen, James S Welsh, et al.
Pageof 10